scholarly journals Undifferentiated embryonic cell transcription factor-1 (UTF1) inhibits the growth of cervical cancer cells by transactivating p27Kip1

2013 ◽  
Vol 34 (7) ◽  
pp. 1660-1668 ◽  
Author(s):  
Xiao-Ling Wu ◽  
Peng-Sheng Zheng
Oncogene ◽  
2001 ◽  
Vol 20 (35) ◽  
pp. 4899-4903 ◽  
Author(s):  
Daniel Ndisang ◽  
Vishwanie Budhram-Mahadeo ◽  
Barbara Pedley ◽  
David S Latchman

2014 ◽  
Vol 7 (5) ◽  
pp. 1409-1413 ◽  
Author(s):  
JUSTYNA K. BRONIARCZYK ◽  
ALICJA WAROWICKA ◽  
ANNA KWAŚNIEWSKA ◽  
MARIA WOHUŃ-CHOLEWA ◽  
WOJCIECH KWAŚNIEWSKI ◽  
...  

2018 ◽  
Author(s):  
Ethan Luc Morgan ◽  
Andrew Macdonald

Persistent human papillomavirus (HPV) infection is the leading cause of cervical cancer. Although the fundamental link between HPV infection and oncogenesis is established, the specific mechanisms of virus-mediated transformation remain poorly understood. We previously demonstrated that the HPV encoded E6 protein increases the activity of the proto-oncogenic transcription factor STAT3 in primary human keratinocytes; however, the molecular basis for STAT3 activation in cervical cancer remains unclear. Here, we show that STAT3 phosphorylation in HPV positive cervical cancer cells is mediated primarily via autocrine activation by the pro-inflammatory cytokine Interleukin 6 (IL-6). Antibody-mediated blockade of IL-6 signalling in HPV positive cells inhibits STAT3 phosphorylation, whereas both recombinant IL-6 and conditioned media from HPV positive cells leads to increased STAT3 phosphorylation within HPV negative cervical cancer cells. Interestingly, we demonstrate that non-conventional activation of the transcription factor NF?B, involving the protein kinase Akt, is required for IL-6 production and subsequent STAT3 activation. Our data provides new insights into the molecular re-wiring of cancer cells by HPV E6. We reveal that activation of an IL-6 signalling axis drives the autocrine and paracrine phosphorylation of STAT3 within HPV positive cervical cancers cells. Greater understanding of this pathway provides a potential opportunity for the use of existing clinically approved drugs for the treatment of HPV-mediated cervical cancer.


Sign in / Sign up

Export Citation Format

Share Document